Opinion of the Transparency Council – posaconazole
At its meeting on 14 April 2025, the Transparency Council adopted opinion No. 66/2025 on the inclusion of medicinal products containing the active substance posaconazole in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics